Clinical trial
Effects of Betaserc on Vestibular Compensation in Patients Suffering From…
NCT00160238 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00160238 |
|---|---|
| Title | Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy |
| Official title | A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Meniere's Disease |
| Intervention type | Drug |
| Interventions | Betahistine 24 mg bid (Betaserc) |
| Enrollment | 20 |
| Start date | Jan 1, 2003 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 22, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: